Cerebrospinal Fluid Biomarker Profile in Atypical Alzheimer’s Disease
Revista de Neurología · 2025
DOI: 10.31083/rn36399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista de Neurología, 2025. Verfasst von Elisa Martínez Campos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Neurología, Hospital Universitario de Navarra, 31008 Pamplona, España. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins, Amyloid beta-Peptides, Peptide Fragments. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Introduction
Cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) are essential for the early identification of non-amnestic phenotypes. Increased levels of total tau (t-tau) and phosphorylated tau (p-tau) have been reported in atypical AD cases, although the specific pattern remains a subject of debate. This study aimed to evaluate CSF biomarker profiles in relation to clinical phenotype. Materials and Methods: A retrospective review was performed, analyzing demographic data, time to diagnosis, clinical phenotype, and core AD biomarkers (beta-amyloid peptide 1-42 (Aβ1-42), t-tau, p-tau) in CSF from patients evaluated at University Hospital in Navarra between 2019 and 2022.
Results
The study included 57 patients (54% female, mean age 67 years), of whom 41 met AD diagnostic criteria. Among these, 10 patients (25%) presented with atypical phenotypes (50% aphasic, 30% frontal, 20% mixed non-amnestic). Compared with the amnestic phenotype, the atypical group exhibited significantly higher t-tau (562.9 pg/mL vs 320.3 pg/mL, p = 0.021) and p-tau (81.5 pg/mL vs 37.7 pg/mL, p = 0.016) levels, independent of age, sex, and time to diagnosis.
Conclusions
Atypical cases demonstrated increased tau levels, suggesting earlier and more extensive cortical damage than the amnestic phenotype. These findings underscore the significance of CSF biomarkers in phenotypic differentiation, disease course prediction, and individualized treatment strategies for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Neurología, Hospital Universitario de Navarra, 31008 Pamplona, España.
Zitieren
APA
Martínez Campos, E., Tellechea Aramburo, P., Sánchez Ruiz de Gordoa, J., & Larumbe Ilundain, R. (2025). Cerebrospinal Fluid Biomarker Profile in Atypical Alzheimer’s Disease. Revista de Neurología. https://doi.org/10.31083/rn36399
Vancouver
Martínez Campos E, Tellechea Aramburo P, Sánchez Ruiz de Gordoa J, Larumbe Ilundain R. Cerebrospinal Fluid Biomarker Profile in Atypical Alzheimer’s Disease. Revista de Neurología. 2025. doi:10.31083/rn36399
BibTeX
@article{MartnezCampos2025,
author = {Martínez Campos, Elisa and Tellechea Aramburo, Paula and Sánchez Ruiz de Gordoa, Javier and Larumbe Ilundain, Rosa},
title = {Cerebrospinal Fluid Biomarker Profile in Atypical Alzheimer’s Disease},
journal = {Revista de Neurología},
year = {2025},
doi = {10.31083/rn36399}
}
EUVIMED